GNS Healthcare (GNS), a Cambridge, Mass.-based precision medicine company, raised $23m in Series D funding.
The round was led by Cigna Ventures, a strategic corporate venture capital partner and wholly owned indirect subsidiary of Cigna Corporation (NYSE: CI), with participation from Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, as well as former Caesar’s CEO and Aetna Division President Gary Loveman.
The company intends to use the funds to expand its business reach.
Led by Colin Hill, Chairman, CEO and Co-Founder, GNS Healthcare aims to solve healthcare’s matching problem for health plans, biopharma companies, and health systems transforming massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals.
The GNS causal learning and simulation platform, REFS, analyzes data sets beyond correlation, instead inferring causal mechanisms between variables to answer questions such as: How will the patient respond to this treatment? What if we choose one intervention over another?